Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medicinal Chemistry
  4. Volume 32, Issue 10
  5. Article
Volume 32, Issue 10
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

Neopterin (NEO) is an inflammatory biomarker with proposed diagnostic value in cardiovascular diseases. Some correlations have been discovered between NEO levels and the incidence, severity, and adverse outcomes of heart failure (HF). However, there are discrepancies in the results reported in the literature.

Methods

We conducted a systematic review and meta-analysis of studies comparing urinary and blood NEO concentrations between individuals with HF, cardiac insufficiency, or dilated cardiomyopathy (DCM) with control groups or those monitoring the role of NEO concentrations as a predictive marker of adverse outcomes in HF patients.

Results

A total of 24 studies that met the inclusion criteria were reviewed. The studies demonstrated the alteration of NEO in blood or urine samples in subjects with HF, cardiac insufficiency, or DCM compared with control groups. Also, reviewing the studies suggested a link between reduced ejection fraction, higher NYHA classes, and a higher risk of adverse cardiac outcomes with increased NEO levels. The meta-analysis of three studies revealed a significant increase in serum NEO levels in HF cases compared to that in healthy controls with an effect size of 3.72 (95% CI 0.16 to 7.28; = 0.04).

Conclusion

Meta-analysis demonstrated a significant difference between serum NEO levels of HF cases and healthy subjects. This evidence implies the potential of serum NEO as a valuable diagnostic biomarker in HF patients. Also, the review of the studies revealed the prognostic potential of NEO. Further research is required to assess the usefulness of NEO as a diagnostic/prognostic biomarker for HF.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673258661231003045907
2023-10-11
2025-03-31

  • From This Site

    /content/journals/cmc/10.2174/0109298673258661231003045907
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. DogheimG.M. AmrallaM.T. WeridaR.H. Role of neopterin as an inflammatory biomarker in congestive heart failure with insights on effect of drug therapies on its level.Inflammopharmacology20223051617162210.1007/s10787‑022‑01028‑5 35876931
     [Google Scholar]
  2. SeferovićP.M. VardasP. JankowskaE.A. MaggioniA.P. TimmisA. MilinkovićI. PolovinaM. GaleC.P. LundL.H. LopatinY. LainscakM. SavareseG. HuculeciR. KazakiewiczD. CoatsA.J.S. The heart failure association atlas: Heart failure epidemiology and management statistics 2019.Eur. J. Heart Fail.202123690691410.1002/ejhf.2143 33634931
     [Google Scholar]
  3. RossignolP. HernandezA.F. SolomonS.D. ZannadF. Heart failure drug treatment.Lancet2019393101751034104410.1016/S0140‑6736(18)31808‑7 30860029
     [Google Scholar]
  4. BoorsmaE.M. ter MaatenJ.M. DammanK. DinhW. GustafssonF. GoldsmithS. BurkhoffD. ZannadF. UdelsonJ.E. VoorsA.A. Congestion in heart failure: A contemporary look at physiology, diagnosis and treatment.Nat. Rev. Cardiol.2020171064165510.1038/s41569‑020‑0379‑7 32415147
     [Google Scholar]
  5. LiR. HeH. FangS. HuaY. YangX. YuanY. LiangS. LiuP. TianY. XuF. ZhangZ. HuangY. Time series characteristics of serum branched-chain amino acids for early diagnosis of chronic heart failure.J. Proteome Res.20191852121212810.1021/acs.jproteome.9b00002 30895791
     [Google Scholar]
  6. HouY. Adrian-SegarraJ.M. RichterM. KubinN. ShinJ. WernerI. WaltherT. SchönburgM. PölingJ. WarneckeH. Animal models and “Omics” technologies for identification of novel biomarkers and drug targets to prevent heart failure.BioMed Res. Int.2015201521291010.1155/2015/212910
     [Google Scholar]
  7. StöhrR. BrandenburgV.M. HeineG.H. MaederM.T. LeibundgutG. SchuhA. JekerU. PfistererM. Sanders-van WijkS. Brunner-la RoccaH.P. Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial.Eur. J. Heart Fail.202022470170910.1002/ejhf.1749 32020782
     [Google Scholar]
  8. SarheneM. WangY. WeiJ. HuangY. LiM. LiL. AcheampongE. ZhengcanZ. XiaoyanQ. YunshengX. JingyuanM. XiumeiG. GuanweiF. Biomarkers in heart failure: The past, current and future.Heart Fail. Rev.201924686790310.1007/s10741‑019‑09807‑z 31183637
     [Google Scholar]
  9. AlbarZ. AlbakriM. HajjariJ. KarnibM. JanusS.E. Al-KindiS.G. Inflammatory markers and risk of heart failure with reduced to preserved ejection fraction.Am. J. Cardiol.2022167687510.1016/j.amjcard.2021.11.045 34986991
     [Google Scholar]
  10. MohamadM. EbeidS. Shawky KhaterM. AlsadanyM. Interferon-gamma-inducible guanosine triphosphate cyclohydrolase 1 (GTP-CH1) pathway is associated with frailty in Egyptian elderly.Rep. Biochem. Mol. Biol.2018715258 30324118
     [Google Scholar]
  11. CastilloE.C. Vázquez-GarzaE. Yee-TrejoD. García-RivasG. Torre-AmioneG. What is the role of the inflammation in the pathogenesis of heart failure?Curr. Cardiol. Rep.2020221113910.1007/s11886‑020‑01382‑2 32910299
     [Google Scholar]
  12. WiedermannC.J. BeimpoldH. HeroldM. KnappE. BraunsteinerH. Increased levels of serum neoprotein and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha.J. Am. Coll. Cardiol.19932271897190110.1016/0735‑1097(93)90776‑W 8245346
     [Google Scholar]
  13. DemirŞ. EdeH. KaplanM. YavuzF. YücelC. Kurtİ.H. Neopterin as a novel marker; well correlated with mortality and morbidity in patients with advanced systolic heart failure.Acta Cardiol.201974321622110.1080/00015385.2018.1478266 29914304
     [Google Scholar]
  14. PageM.J. McKenzieJ.E. BossuytP.M. BoutronI. HoffmannT.C. MulrowC.D. ShamseerL. TetzlaffJ.M. AklE.A. BrennanS.E. ChouR. GlanvilleJ. GrimshawJ.M. HróbjartssonA. LaluM.M. LiT. LoderE.W. Mayo-WilsonE. McDonaldS. McGuinnessL.A. StewartL.A. ThomasJ. TriccoA.C. WelchV.A. WhitingP. MoherD. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.BMJ202137271n7110.1136/bmj.n71 33782057
     [Google Scholar]
  15. WanX. WangW. LiuJ. TongT. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.BMC Med. Res. Methodol.201414113510.1186/1471‑2288‑14‑135 25524443
     [Google Scholar]
  16. SterneJ.A.C. SavovićJ. PageM.J. ElbersR.G. BlencoweN.S. BoutronI. CatesC.J. ChengH.Y. CorbettM.S. EldridgeS.M. EmbersonJ.R. HernánM.A. HopewellS. HróbjartssonA. JunqueiraD.R. JüniP. KirkhamJ.J. LassersonT. LiT. McAleenanA. ReevesB.C. ShepperdS. ShrierI. StewartL.A. TillingK. WhiteI.R. WhitingP.F. HigginsJ.P.T. RoB 2: A revised tool for assessing risk of bias in randomised trials.BMJ2019366l489810.1136/bmj.l4898 31462531
     [Google Scholar]
  17. CarusoR. CampoloJ. VerdeA. BottaL. CozziL. ParoliniM. MilazzoF. NoniniS. MartinelliL. PainoR. MarracciniP. FrigerioM. Relationship between early inflammatory response and clinical evolution of the severe multiorgan failure in mechanical circulatory support-treated patients.Mediators Inflamm.201420141910.1155/2014/281790 25132729
     [Google Scholar]
  18. DjordjevicV.B. StojanovicI. CosicV. ZvezdanovicL. Deljanin-IlicM. DimicS. KundalicB. CvetkovicT. Jevtovic-StoimenovT. Serum neopterin, nitric oxide, inducible nitric oxide synthase and tumor necrosis factor-α levels in patients with ischemic heart disease.Clin. Chem. Lab. Med.20084681149115510.1515/CCLM.2008.213 18605955
     [Google Scholar]
  19. GrebeS.O. KuhlmannU. FoglD. LuyckxV.A. MuellerT.F. Macrophage activation is associated with poorer long-term outcomes in renal transplant patients.Clin. Transplant.201125574475410.1111/j.1399‑0012.2010.01345.x 20964718
     [Google Scholar]
  20. IshikawaT. HamelM. ZhuB.L. LiD.R. ZhaoD. MichiueT. MaedaH. Comparative evaluation of postmortem serum concentrations of neopterin and C-reactive protein.Forensic Sci. Int.20081792-313514310.1016/j.forsciint.2008.04.021 18541395
     [Google Scholar]
  21. JohnstonD.T. GagosM. RaioN. RagoliaL. ShenoudaD. Davis-LortonM.A. De LeonJ.R. Alterations in serum neopterin correlate with thrombolysis in myocardial infarction risk scores in acute coronary syndromes.Coron. Artery Dis.200617651151610.1097/00019501‑200609000‑00003 16905962
     [Google Scholar]
  22. KaskiJ.C. Consuegra-SanchezL. Fernandez-BergesD.J. Cruz-FernandezJ.M. Garcia-MollX. MarrugatJ. MostazaJ. Toro-CebadaR. González-JuanateyJ.R. Guzmán-MartínezG. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome.Atherosclerosis2008201117618310.1016/j.atherosclerosis.2008.01.009 18336825
     [Google Scholar]
  23. KaskiJ.C. Cruz-FernándezJ.M. Fernández-BergésD. García-MollX. Martín JadraqueL. MostazaJ. López García-ArandaV. González JuanateyJ.R. Castro BeirasA. Martín LuengoC. Alonso GarcíaA. López-BescósL. Marcos GómezG. Inflammation markers and risk stratification in patients with acute coronary syndromes: Design of the SIESTA study (Systemic inflammation evaluation in patients with non-ST segment elevation Acute coronary syndromes).Rev. Esp. Cardiol.200356438939510.1157/13045655 12689574
     [Google Scholar]
  24. KluzK. ParenicaJ. KubkovaL. LittnerovaS. TomandlJ. PoloczekM. TomanO. TesakM. CermakovaZ. GottwaldovaJ. ManousekJ. Pavkova GoldbergovaM. SpinarJ. JarkovskyJ. Unstable angina pectoris prior to ST elevation myocardial infarction in patients treated with primary percutaneous coronary intervention has no influence on prognosis.Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.2015159225125810.5507/bp.2014.003 24457834
     [Google Scholar]
  25. KweeL.C. NeelyM.L. GrassE. GregoryS.G. RoeM.T. OhmanE.M. FoxK.A.A. WhiteH.D. ArmstrongP.W. BowsmanL.M. HaasJ.V. DuffinK.L. ChanM.Y. ShahS.H. Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome.Physiol. Genomics2019511050651510.1152/physiolgenomics.00033.2019 31530226
     [Google Scholar]
  26. LiuZ.Y. LiY.D. Relationship between serum neopterin levels and coronary heart disease.Genet. Mol. Res.20131244222422910.4238/2013.October.7.8 24114217
     [Google Scholar]
  27. LoccaD. Bucciarelli-DucciC. FerranteG. La MannaA. KeenanN.G. GrassoA. BarlisP. Del FuriaF. PrasadS.K. KaskiJ.C. PennellD.J. Di MarioC. New universal definition of myocardial infarction applicable after complex percutaneous coronary interventions?JACC Cardiovasc. Interv.20103995095810.1016/j.jcin.2010.06.015 20850095
     [Google Scholar]
  28. LyuY. JiangX. DaiW. The roles of a novel inflammatory neopterin in subjects with coronary atherosclerotic heart disease.Int. Immunopharmacol.201524216917210.1016/j.intimp.2014.11.013 25479720
     [Google Scholar]
  29. MillerW.L. HartmanK.A. HodgeD.O. HartmanS. StruckJ. MorgenthalerN.G. BergmannA. JaffeA.S. Response of novel biomarkers to BNP infusion in patients with decompensated heart failure: A multimarker paradigm.J. Cardiovasc. Transl. Res.20092452653510.1007/s12265‑009‑9121‑x 20560012
     [Google Scholar]
  30. PihlstrømH. MjøenG. MärzW. Olav DahleD. AbediniS. HolmeI. FellströmB. JardineA. PilzS. HoldaasH. Neopterin is associated with cardiovascular events and all-cause mortality in renal transplant patients.Clin. Transplant.201428111111910.1111/ctr.12285 24372612
     [Google Scholar]
  31. RagabM. HassanH. ZaytounT. RefaiW. RocksB. ElsammakM. Evaluation of serum neopterin, high-sensitivity C-reactive protein and thiobarbituric acid reactive substances in Egyptian patients with acute coronary syndromes.Exp. Clin. Cardiol.2005104250255 19641675
     [Google Scholar]
  32. RayK.K. MorrowD.A. SabatineM.S. ShuiA. RifaiN. CannonC.P. BraunwaldE. Long-term prognostic value of neopterin: A novel marker of monocyte activation in patients with acute coronary syndrome.Circulation2007115243071307810.1161/CIRCULATIONAHA.106.666511 17548728
     [Google Scholar]
  33. SchnabelR.B. SchulzA. MessowC.M. LubosE. WildP.S. ZellerT. SinningC.R. RupprechtH.J. BickelC. PeetzD. CambienF. KempfT. WollertK.C. BenjaminE.J. LacknerK.J. MünzelT.F. TiretL. VasanR.S. BlankenbergS. Multiple marker approach to risk stratification in patients with stable coronary artery disease.Eur. Heart J.201031243024303110.1093/eurheartj/ehq322 20852293
     [Google Scholar]
  34. SchumacherM. HalwachsG. TatzberF. FruhwaldF.M. ZweikerR. WatzingerN. EberB. Wilders-TruschnigM. EsterbauerH. KleinW. Increased neopterin in patients with chronic and acute coronary syndromes.J. Am. Coll. Cardiol.199730370370710.1016/S0735‑1097(97)00172‑1 9283529
     [Google Scholar]
  35. SuloG. VollsetS.E. NygårdO. MidttunØ. UelandP.M. EussenS.J.P.M. PedersenE.R. TellG.S. Neopterin and kynurenine–tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study.Int. J. Cardiol.201316821435144010.1016/j.ijcard.2012.12.090 23336953
     [Google Scholar]
  36. van HaelstP.L. LiemA. van BovenA.J. VeegerN.J. van VeldhuisenD.J. Cohen TervaertJ.W. GansR.O. ZijlstraF. Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction.Am. J. Cardiol.200392101201120310.1016/j.amjcard.2003.07.031 14609597
     [Google Scholar]
  37. Van HaelstP.L. TervaertJ.W.C. BijzetJ. Baljé-VolkersC. MayJ.F. LangeveldB. GansR.O.B. Circulating monocytes in patients with acute coronary syndromes lack sufficient interleukin-10 production after lipopolysaccharide stimulation.Clin. Exp. Immunol.2004138236436810.1111/j.1365‑2249.2004.02602.x 15498050
     [Google Scholar]
  38. VarolE. GülcanM. AylakF. OzaydinM. SutçuR. ErdoğanD. DoğanA. Increased neopterin levels and its association with angiographic variables in patients with slow coronary flow: An observational study.Anadolu Kardiyol. Derg.201111869269710.5152/akd.2011.190 22088857
     [Google Scholar]
  39. BarbarashO.L. ZykovM.V. KashtalapV.V. OsokinaA.V. BernsS.A. KaretnikovaV.N. BarbarashL.S. Prognostic value of various markers of inflammation in ST-elevation myocardial infarction.Kardiologiia20115132430 21627609
     [Google Scholar]
  40. PopovE.A. PoluninaE.A. VoroninaL.P. PoluninaO.S. BelyakovaI.S. Analysis of inflammatory marker levels in patients with chronic heart failure.Cardiovasc. Ther. Prev.2018175475210.15829/1728‑8800‑2018‑5‑47‑52
     [Google Scholar]
  41. ShevchenkoA.O. ShevchenkoO.P. OrlovaO.V. TulikovM.V. Neoangiogenesis and coronary atherosclerosis: Diagnostic value of a novel biochemical marker placenta growth factor in patients with ischemic heart disease.Kardiologiia20064611915 17159877
     [Google Scholar]
  42. WetlickaI. KorzeniowskaK. BogdańskiP. KaźmierczakM. ChmaraE. MusialikK. JabłeckaA. The assessment of neopterin concentration in patients with heart failure.Pol. Merkuriusz Lek.201028166256259
     [Google Scholar]
  43. Dominguez-RodriguezA. Abreu-GonzalezP. Juarez-PreraR.A. Arroyo-UcarE. Hernandez-GarciaC. TomeM.C.P. Blanco-PalaciosG.E. KaskiJ.C. Usefulness of serum neopterin levels in acute decompensated heart failure to predict renal dysfunction.Biomarkers201217213413910.3109/1354750X.2011.643486 22188331
     [Google Scholar]
  44. KalmanJ. LevineB. MayerL. PennJ. KukinM.L. PackerM. Prognostic importance of circulating neopterin in heart-failure - evidence for monocyte activation in patients with cardiac cachexia.Circulation1990824315315
     [Google Scholar]
  45. MontagnanaM. LippiG. DaneseE. SalvagnoG.L. CervellinG. GuidiG.C. Serum concentration of neopterin on admission does not improve the diagnostic performance of highly-sensitive troponin I.Clin. Chem. Lab. Med.201250474774810.1515/cclm.2011.829 22149745
     [Google Scholar]
  46. SasakiT. ShishidoT. TakahashiH. ArimotoT. MiyashitaT. MiyamotoT. NitobeJ. WatanabeT. TakeishiY. KubotaI. High serum level of neopterin predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function.Circulation200912018S825S825
     [Google Scholar]
  47. SasakiT. TakeishiY. SuzukiS. NiizekiT. KitaharaT. KatohS. IshinoM. ShishidoT. WatanabeT. KubotaI. High serum level of neopterin is a risk factor of patients with heart failure.Int. J. Cardiol.2010145231810.1016/j.ijcard.2009.11.042 20051294
     [Google Scholar]
  48. YamamotoE. HirataY. TokitsuT. KusakaH. TabataN. TsujitaK. YamamuroM. KaikitaK. WatanabeH. HokimotoS. MaruyamaT. OgawaH. The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction.ESC Heart Fail.201631535910.1002/ehf2.12070 27774267
     [Google Scholar]
  49. ShaoZ. ZhangR. BorowskiA.G. ThakurA. TangW.H.W. Elevated urinary neopterin levels are associated with cardiac and functional impairment in patients with chronic systolic heart failure.J. Card. Fail.2011178S28S2810.1016/j.cardfail.2011.06.095
     [Google Scholar]
  50. AukrustP. UelandT. MüllerF. AndreassenA.K. NordøyI. AasH. KjekshusJ. SimonsenS. FrølandS.S. GullestadL. Elevated circulating levels of C-C chemokines in patients with congestive heart failure.Circulation199897121136114310.1161/01.CIR.97.12.1136 9537339
     [Google Scholar]
  51. VonhofS. BrostB. Stille-SiegenerM. GrumbachI.M. KreuzerH. FigullaH.R. Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy.Int. J. Cardiol.199863323724410.1016/S0167‑5273(97)00332‑X 9578350
     [Google Scholar]
  52. Wietlicka-KokoszanekI. JableckaA. SmolarekI. BogdanskiP. ChmaraE. KorzeniowskaK. KazmierczakM. KazmierczakE. MusialikK. Neopterin as a prognostic marker in patients with chronic heart failure.Med. Sci. Monit.2010165CR232CR237 20424550
     [Google Scholar]
  53. AvanzasP. Arroyo-EspligueroR. QuilesJ. RoyD. KaskiJ.C. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris.Eur. Heart J.200526545746310.1093/eurheartj/ehi111 15684278
     [Google Scholar]
  54. BergK.S. StensethR. PleymH. WahbaA. VidemV. Neopterin predicts cardiac dysfunction following cardiac surgery.Interact. Cardiovasc. Thorac. Surg.201521559860310.1093/icvts/ivv219 26265068
     [Google Scholar]
  55. BershovaT.V. ShmatkovaY.V. IvanovA.P. BakanovM.I. BasarginaE.N. ZurabovaR.B. MonaenkovaS.V. GerasimovaY.V. Biochemical and immunological markers of insufficiency of blood circulation in children with cardiomyopathies.Biochem. Suppl. Ser. B: Biomed. Chem.20071437037610.1134/S1990750807040142
     [Google Scholar]
  56. BrunkhorstF.M. ClarkA.L. ForyckiZ.F. AnkerS.D. Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: The potential importance of bacterial translocation.Int. J. Cardiol.199972131010.1016/S0167‑5273(99)00118‑7 10636626
     [Google Scholar]
  57. CaforioA.L.P. GoldmanJ.H. BaigM.K. MahonN.J. HavenA.J. SouberbielleB.E. HoltD.W. DalgleishA.G. McKennaW.J. Elevated serum levels of soluble interleukin-2 receptor, neopterin and β-2-microglobulin in idiopathic dilated cardiomyopathy: Relation to disease severity and autoimmune pathogenesis.Eur. J. Heart Fail.20013215516310.1016/S1388‑9842(00)00148‑3 11246052
     [Google Scholar]
  58. CarusoR. De ChiaraB. CampoloJ. VerdeA. MuscaF. BelliO. ParoliniM. CozziL. MoreoA. FrigerioM. ParodiO. Neopterin levels are independently associated with cardiac remodeling in patients with chronic heart failure.Clin. Biochem.2013461-2949810.1016/j.clinbiochem.2012.10.022 23103705
     [Google Scholar]
  59. CarusoR. VerdeA. CampoloJ. MilazzoF. RussoC. BoroniC. ParoliniM. TrunfioS. PainoR. MartinelliL. FrigerioM. ParodiO. Severity of oxidative stress and inflammatory activation in end-stage heart failure patients are unaltered after 1 month of left ventricular mechanical assistance.Cytokine201259113814410.1016/j.cyto.2012.04.018 22579113
     [Google Scholar]
  60. Estévez-LoureiroR. Recio-MayoralA. Sieira-Rodríguez-MoretJ.A. Trallero-AraguásE. KaskiJ.C. Neopterin levels and left ventricular dysfunction in patients with chronic stable angina pectoris.Atherosclerosis2009207251451810.1016/j.atherosclerosis.2009.04.032 19577753
     [Google Scholar]
  61. FuchsD. SamsonovM. TilzG.P. ReibneggerG. BelenkovJ.N. NassonovE.L. WachterH. Stimulated cellular immune system in patients with congestive heart failure.Clin. Chem. Lab. Med.199331311111410.1515/cclm.1993.31.3.111 8490055
     [Google Scholar]
  62. HennigF. StepanenkoA.V. LehmkuhlH.B. KukuckaM. DandelM. KrabatschT. HetzerR. PotapovE.V. Neurohumoral and inflammatory markers for prediction of right ventricular failure after implantation of a left ventricular assist device.Gen. Thorac. Cardiovasc. Surg.2011591192410.1007/s11748‑010‑0669‑9 21225395
     [Google Scholar]
  63. LanserL. PölzlG. FuchsD. WeissG. KurzK. Neopterin is associated with disease severity and outcome in patients with non-ischaemic heart failure.J. Clin. Med.2019812223010.3390/jcm8122230 31861167
     [Google Scholar]
  64. MjelvaØ.R. SvingenG.F.T. PedersenE.K.R. SeifertR. KvaløyJ.T. MidttunØ. UelandP.M. NordrehaugJ.E. NygårdO. NilsenD.W.T. Fibrinogen and neopterin is associated with future myocardial infarction and total mortality in patients with stable coronary artery disease.Thromb. Haemost.20181184778790 29458232
     [Google Scholar]
  65. NazerB. RayK.K. SloanS. SciricaB. MorrowD.A. CannonC.P. BraunwaldE. Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome.Eur. Heart J.201132111390139710.1093/eurheartj/ehr032 21345849
     [Google Scholar]
  66. SamsonovM. LopatinJ. TilzG.P. Artner-DworzakE. NassonovE. MareevV. BelenkovJ. WachterH. FuchsD. The activated immune system and the renin-angiotensin-aldosterone system in congestive heart failure.J. Intern. Med.19982432939810.1046/j.1365‑2796.1998.00240.x 9566636
     [Google Scholar]
  67. ShaoZ. ZhangR. ShresthaK. BorowskiA.G. SchusterA. ThakurA. HazenS.L. TangW.H.W. Usefulness of elevated urine neopterin levels in assessing cardiac dysfunction and exercise ventilation inefficiency in patients with chronic systolic heart failure.Am. J. Cardiol.2014113111839184310.1016/j.amjcard.2014.03.016 24837262
     [Google Scholar]
  68. WojciechowskaC. WodnieckiJ. WojniczR. RomukE. JachećW. TomasikA. Skrzep-PoloczekB. SpinczykB. Nowalany-KozielskaE. Neopterin and beta-2 microglobulin relations to immunity and inflammatory status in nonischemic dilated cardiomyopathy patients.Mediators Inflamm.201420141810.1155/2014/585067 25214716
     [Google Scholar]
  69. DogheimG.M. KhairatI. OmranG.A. El-HaggarS.M. AmrawyA.M.E. WeridaR.H. Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients.Eur. J. Clin. Pharmacol.202278694395410.1007/s00228‑022‑03290‑6 35238960
     [Google Scholar]
  70. BaraniJ. MattiassonI. LindbladB. GottsäterA. Cardiac function, inflammatory mediators and mortality in critical limb ischemia.Angiology200657443744410.1177/0003319706290743 17022379
     [Google Scholar]
  71. SamsonovM. FuchsD. ReibneggerG. BelenkovJ.N. NassonovE.L. WachterH. Patterns of serological markers for cellular immune activation in patients with dilated cardiomyopathy and chronic myocarditis.Clin. Chem.199238567868010.1093/clinchem/38.5.678 1582019
     [Google Scholar]
  72. SpencerM.E. JainA. MatteiniA. BeamerB.A. WangN.Y. LengS.X. PunjabiN.M. WalstonJ.D. FedarkoN.S. Serum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fat.J. Gerontol. A Biol. Sci. Med. Sci.201065A885886510.1093/gerona/glq066 20478905
     [Google Scholar]
  73. ÜnüvarS. TanrıverdiZ. AslanhanH. Potential prognostic role of immune system activation marker neopterin in patients with type 2 diabetes.J. Med. Biochem.201837446546910.2478/jomb‑2018‑0004 30584406
     [Google Scholar]
  74. SchennachH. MurrC. GächterE. MayersbachP. SchönitzerD. FuchsD. Factors influencing serum neopterin concentrations in a population of blood donors.Clin. Chem.200248464364510.1093/clinchem/48.4.643 11901063
     [Google Scholar]
  75. PolyakovaE.A. MikhaylovE.N. SoninD.L. CheburkinY.V. GalagudzaM.M. Neurohumoral, cardiac and inflammatory markers in the evaluation of heart failure severity and progression.J. Geriatr. Cardiol.20211814766 33613659
     [Google Scholar]
  76. NechitaV.I. HajjarN.A. DruganC. CătanăC.S. MoişE. NechitaM.A. GraurF. Chitotriosidase and neopterin as potential biomarkers for the evaluation of complicated cholecystitis-A pilot study.J. Clin. Med.2023124164110.3390/jcm12041641 36836175
     [Google Scholar]
  77. HojdaS.E. ChisI.C. ClichiciS. Biomarkers in pulmonary arterial hypertension.Diagnostics20221212303310.3390/diagnostics12123033 36553040
     [Google Scholar]
  78. SaghazadehA. RezaeiN. Elevated neopterin in tuberculosis and co-infection with HIV and the effect of treatment: A systematic review, meta-analysis, and meta-regression.Int. Immunopharmacol.202211110914710.1016/j.intimp.2022.109147 35973370
     [Google Scholar]
  79. LiC. WangY. QiuQ. ShiT. WuY. HanJ. ChaiX. WangW. Qishenyiqi protects ligation-induced left ventricular remodeling by attenuating inflammation and fibrosis via STAT3 and NF-κB signaling pathway.PLoS One201498e10425510.1371/journal.pone.0104255 25122164
     [Google Scholar]
  80. KrumH. AshtonE. ReidC. KalffV. RogersJ. AmarenaJ. SinghB. TonkinA. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.J. Card. Fail.20071311710.1016/j.cardfail.2006.09.008 17338996
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673258661231003045907
Loading
Neopterin as a Potential Biomarker for the Early Diagnosis of Heart Failure: A Systematic Review and Meta-analysis
Curr. Med. Chem. 32, 2021 (2025); https://doi.org/10.2174/0109298673258661231003045907
/content/journals/cmc/10.2174/0109298673258661231003045907
/content/journals/cmc/10.2174/0109298673258661231003045907
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article. Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): Biomarker; dilated cardiomyopathy; heart failure; myocardial failure; neopterin; serum

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test